Tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV) conferred 49% to 68% protection against any rotavirus diarrhea and 61% to 100% protection against severe disease in clinical trials.
Does Tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV) prevent rotavirus diarrhea in children?
RRV-TV is an effective vaccine for preventing rotavirus diarrhea and severe disease in children in industrialized countries.
Effect estimate: 49% to 68% protection
Rotavirus, the most common diarrheal pathogen in children worldwide, causes approximately one third of diarrhea-associated hospitalizations and 800,000 deaths per year. Because natural infection reduces the incidence and severity of subsequent episodes, rotavirus diarrhea might be controlled through vaccination. Serotypespecific immunity may play a role in protection from disease. Tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV) (which contains a rhesus rotavirus with serotype G3 specificity and reassortant rhesus-human rotaviruses with G1, G2, and G4 specificity) provides coverage against the four common serotypes of human rotavirus. In clinical trials in industrialized countries, RRV-TV conferred 49% to 68% protection against any rotavirus diarrhea and 61% to 100% protection against severe disease. This vaccine was licensed by the U.S. Food and Drug Administration on August 31, 1998, and should be cost-effective in reducing diarrheal diseases in industrialized countries. The vaccine's efficacy and cost-effectiveness in developing countries should be evaluated.
Parashar et al. (Tue,) conducted a review in Rotavirus diarrhea. Tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV) was evaluated on Any rotavirus diarrhea and severe disease (49% to 68% protection). Tetravalent rhesus-human reassortant rotavirus vaccine (RRV-TV) conferred 49% to 68% protection against any rotavirus diarrhea and 61% to 100% protection against severe disease in clinical trials.